VBI Vaccines Inc. (NASDAQ:VBIV) Short Interest Up 145.4% in April

VBI Vaccines Inc. (NASDAQ:VBIV) saw a large growth in short interest in April. As of April 15th, there was short interest totalling 709,500 shares, a growth of 145.4% from the March 31st total of 289,100 shares. Based on an average daily volume of 445,600 shares, the short-interest ratio is presently 1.6 days. Currently, 2.7% of the company’s stock are short sold.

VBI Vaccines Stock Down 4.2 %

VBI Vaccines stock traded down $0.03 during midday trading on Friday, reaching $0.57. The company’s stock had a trading volume of 187,246 shares, compared to its average volume of 369,938. The company has a market cap of $16.32 million, a P/E ratio of -0.05 and a beta of 1.93. The business has a 50-day simple moving average of $0.61 and a 200-day simple moving average of $0.61. VBI Vaccines has a fifty-two week low of $0.45 and a fifty-two week high of $3.47.

Analysts Set New Price Targets

Separately, StockNews.com started coverage on shares of VBI Vaccines in a research report on Friday. They issued a “sell” rating on the stock.

About VBI Vaccines

VBI Vaccines Inc, a biopharmaceutical company, develops and sells vaccines to treat immuno-oncology and infectious disease. It offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. The company also develops VBI-2601, an immunotherapeutic candidate for the treatment of chronic HBV infection; VBI-1901, a glioblastoma vaccine immunotherapeutic candidate, which is in Phase I/IIa clinical study to treat solid tumors; VBI-1501, a prophylactic cytomegalovirus vaccine candidate that has completed Phase I clinical trial; and VBI-2501 that is in preclinical trial to treat Zika virus.